Vivos Therapeutics Plans Rights Offering to Raise Capital at Premium to Current Price

summarizeSummary

Vivos Therapeutics, facing financial distress, announced plans for a rights offering to raise capital, with a proposed exercise price significantly above its current stock price.

check_boxKey Events

• Proposed Rights Offering

  Vivos Therapeutics intends to file a registration statement for a rights offering to distribute transferable subscription rights to shareholders as a dividend, aiming to raise additional capital.

• Premium Exercise Price

  The preliminary exercise price for the rights is set at the greater of $1.25 per share or 20% above the market price on the day before the record date, which is a significant premium to the current stock price of $0.5445.

• Subsequent 'Exploding' Rights

  Upon exercise of a right, holders are expected to receive a second nine-month trading right with an even higher expected exercise price (greater of $1.75 per share or 40% above market).

• Critical Capital Raise

  This initiative is crucial for the company, which has a 'going concern' warning and faces Nasdaq delisting risk, to fund operations and general corporate purposes.

auto_awesomeAnalysis

Vivos Therapeutics, a company facing significant financial challenges including a 'going concern' warning and Nasdaq non-compliance, announced its intention to pursue a rights offering. This move is critical for securing additional capital to fund operations. While the offering is still subject to regulatory approval and other conditions, the proposed exercise price of at least $1.25 per share (or 20% above market) is a notable premium to the current stock price of $0.5445, suggesting an attempt to raise funds at a higher valuation. This strategy aims to provide existing shareholders an opportunity to participate and potentially mitigate dilution at current market levels, which is a more favorable approach than a deeply discounted offering.